Literature DB >> 29524866

Feasibility and preliminary safety of nitric oxide releasing solution as a treatment for bovine mastitis.

Gilly Regev1, James Martins2, Michael P Sheridan2, Jonathan Leemhuis2, James Thompson3, Christopher Miller4.   

Abstract

Nitric oxide-releasing solution (NORS) is a liquid formulation that releases nitric oxide, a broad spectrum antimicrobial, single electron nitroxide radical. This solution was investigated as a potential antimicrobial treatment for bovine mastitis (BM). Three experiments were performed: a) NORS' effect on Staphylococcus aureus and Escherichia coli in an in vitro model; b) NORS' effect on milk obtained from dairy cows showing symptoms of clinical mastitis; and c) the consequences of administering NORS to healthy milking cattle using a dose-escalating in vivo study. Metabolite concentrations were estimated in their blood for methaemoglobin and nitrite; also, milk nitrite concentration and somatic cell count (SCC) were measured to study possible mammary gland inflammation following treatment. NORS lowered the bacterial concentration in all infected samples, in a time- and milk-diluted dependant fashion. Blood methemoglobin concentrations following treatment were all within the normal range for cattle. However, blood and milk nitrite concentrations increased initially but, during the next 24 h, returned to normal range, as did SCC, without any clinical signs of mammary gland inflammation. NORS, if shown to be effective, could be an alternative treatment for mastitis with a shorter clearance time.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial; Bovine mastitis; Nitric oxide; Preliminary safety study

Mesh:

Substances:

Year:  2018        PMID: 29524866     DOI: 10.1016/j.rvsc.2018.02.009

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  1 in total

1.  Differences in Clinical Outcomes between Smokers and Non-Smokers infected with COVID-19.

Authors:  N H Abdulsada Al-Ghuraibawi; S Zeki Al-Fadhel; D M Mohammed Ali; H Kadhem Al-Hakeim
Journal:  Arch Razi Inst       Date:  2022-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.